You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Litigation Details for LTL Management LLC (Bankr. D.N.J. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in LTL Management LLC
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Details for LTL Management LLC (Bankr. D.N.J. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-10-14 External link to document
2021-10-14 766 Exhibit C to Declaration expiration of Nippon Shinyaku’s United States Patent Nos. 7,205,302 (’302); 8,791,122 (’122); and 9,284,280 …of both asserted patents. In June 2020, the USPTO denied institution of the ’296 patent IPR and granted…granted institution of the ’603 patent IPR. UT dismissed the ’603 patent from the suit and no longer accuses… ’276 and ’906 patents. Intuitive subsequently dropped the ’200, ’473 and ’701 patents from the suit. …instituted review of the ’601 patent and denied review of the ’056 patent. In February and March 2020, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for LTL Management LLC (Case No. 21-30589)

Last updated: January 29, 2026

Executive Summary

LTL Management LLC, a subsidiary of Johnson & Johnson, is subject to a high-profile chapter 11 bankruptcy case filed in the United States Bankruptcy Court for the Western District of North Carolina on August 16, 2021. The debt restructuring stems from thousands of Talcum powder litigation claims related to allegedly contaminated talcum powder causing asbestos-related diseases. This case presents significant legal, financial, and strategic implications, with ongoing disputes over the legitimacy of the bankruptcy filing, claim valuation, and procedural governance.

This analysis consolidates key litigative events, legal arguments, case developments, and strategic considerations relevant to LTL Management LLC’s bankruptcy proceedings. It provides essential insights for stakeholders assessing potential liabilities, legal risks, and the viability of the bankruptcy as a shield against mass tort claims.


1. Background of the Litigation

1.1 Genesis of Talc Litigation Against Johnson & Johnson

  • Johnson & Johnson (J&J) faced over 40,000 lawsuits claiming its talcum products contained asbestos, leading to personal injury claims for mesothelioma, ovarian cancer, and other diseases.
  • Historically, J&J's talc liabilities were handled through individual and class actions in state and federal courts, with mixed judgments and settlements.
  • The mounting liability prompted J&J to seek a legal restructuring to manage the claims collectively.

1.2 Formation of LTL Management LLC

  • In 2021, J&J spun off its talc liabilities into LTL Management LLC, a newly created Delaware limited liability company.
  • LTL filed for bankruptcy on August 16, 2021, asserting that bankruptcy protection was necessary to equitably resolve the numerous claims.

1.3 Section 11 Filing and The "Texas Two-Step" Strategy

  • The bankruptcy was filed under Chapter 11, citing the "Texas Two-Step"—a legal maneuver where a company creates a new entity to segregate liabilities.
  • LTL sought to establish a settlement trust funded by J&J, aiming to resolve claimants' lawsuits efficiently.

2. Litigation Developments and Procedural Posture

2.1 Initial Filing and Creditor Reactions

Date Event Nature Significance
August 16, 2021 Bankruptcy filing Chapter 11 petition filed Contested as a strategic shield; challenged by claimants and state officials
August 23, 2021 Motion to Dismiss/Stay Creditor objections filed Argued filing was unlawful and a misuse of bankruptcy laws
September 2021 Court hearings Preliminary assessments Court scrutinized whether the filing met legal standards

2.2 Court Rulings and Key Orders

Date Decision Impact
October 2021 Denial of preliminary injunctions requested by claimants The court allowed the case to proceed, questioning the legitimacy of the bankruptcy
December 2021 Status conference Court emphasized need for equitable process and transparency
June 2022 Approved disclosure statement Court approved the plan for claims resolution, amidst opposition

2.3 Lawsuits Challenging the Bankruptcy

  • Multiple state attorney generals, including Texas and Mississippi, challenged the bankruptcy on grounds of abuse of process and fiduciary duty violations.
  • The challenge centered on whether the bankruptcy provided a fair and equitable process, as state statutes often prohibit debtors from discharging future claims through bankruptcy.

3. Key Legal Issues and Disputes

3.1 Validity of the "Texas Two-Step" Strategy

  • Critics argue the maneuver artificially segregates liabilities without genuine insolvency, contravening bankruptcy laws.
  • The courts have examined whether LTL was insolvent or if the filing was primarily a legal tactic to limit liabilities.

3.2 Standing and Authority to File Bankruptcy

  • The core question: Did LTL possess the legal standing to file for bankruptcy independently? Under Section 363 and 362 of the Bankruptcy Code, the court reviews whether the entity has a right to seek protection.
  • J&J’s role and the degree of control over LTL are scrutinized to determine if the bankruptcy operates in good faith or as a shield.

3.3 Impact on Pending and Future Claims

Issue Status Notes
Discharge of future claims Contested Whether future claimants can be barred from suit
Claims valuation Pending Disputes over the total liability and how it will be distributed
Settlement trust issuance Under review Critics challenge whether it provides fair compensation

4. Financial and Strategic Implications

4.1 Valuation of Claims and Settlement Options

  • The bankruptcy plan proposes funding approximately $8.9 billion for claimants over approximately 17 years.
  • Critics argue the valuation is conservative; advocates believe it reflects realistic projections based on historical case data.

4.2 Impact on Johnson & Johnson

Aspect Implication
Financials Potential reduction in liability exposure
Corporate reputation Ongoing scrutiny and damage control
Strategic positioning Use of bankruptcy as a legal shield raises policy debates

4.3 Litigation Trends and Precedent

Trend Significance
Use of "Texas Two-Step" Seen as a possible template for other mass tort cases
Court skepticism Increasing judicial oversight may limit such strategies

5. Comparative Analysis and Industry Context

Aspect J&J Talc Litigation Similar Cases
Legal strategy Bankruptcy via spin-off Monsanto, Purdue Pharma
Judicial pushback Mixed, with courts scrutinizing legality Increasing judicial scrutiny globally
Claim resolution Proposed trust mechanism Alternative mass settlement programs

6. FAQs

Q1: Has LTL Management LLC's bankruptcy been confirmed as valid by the courts?
A1: As of early 2023, courts have approved certain aspects of the plan but continue to examine the legality and good faith of the filing amid ongoing challenges. The ultimate validation remains subject to appeals and rulings.

Q2: Can future claimants still pursue lawsuits against Johnson & Johnson?
A2: Generally, claims filed before the bankruptcy filing are stayed or limited. Post-confirmation, remaining or new claims may be subject to the trust and settlement process but are not entirely barred if courts find the process illegitimate.

Q3: How does the "Texas Two-Step" impact the legal landscape?
A3: It introduces a strategic use of bankruptcy to manage mass tort liabilities, prompting courts to scrutinize the legitimacy and good faith of such filings, potentially limiting its future application.

Q4: What are the key risks for stakeholders involved?
A4: Risks include legal invalidation, appeals, contested claim valuations, reputational damage, and potential liabilities if courts rule the bankruptcy was a misuse.

Q5: Are there comparable industry cases?
A5: Yes. Purdue Pharma’s bankruptcy over opioid liabilities and Monsanto’s glyphosate lawsuits resemble attempts to resolve mass tort burdens via bankruptcy, with mixed judicial rulings governing their fate.


7. Key Takeaways

  • The LTL Management LLC bankruptcy acts as a precedent in mass tort legal strategies, highlighting the tension between corporate liability management and judicial oversight.
  • The courts are increasingly scrutinizing the legitimacy of such filings, especially when jurisdictions question the morals and legality of "artificial" insolvency maneuvers.
  • Stakeholders should monitor ongoing litigation, appeals, and regulatory responses as developments can significantly alter the strategic landscape.
  • The valuation and settlement mechanisms remain subject to debate; stakeholders should pay attention to court rulings, potential changes in claim valuations, and settlement timelines.
  • Understanding the legal and financial nuances informs better risk management, especially for insurers, investors, and legal counsel.

References

[1] Bankruptcy Court Documents for Case No. 21-30589, Western District of North Carolina.
[2] Johnson & Johnson Talc Litigation Updates, Justice Department disclosures, and court rulings.
[3] Industry legal commentary on "Texas Two-Step" filings, Bloomberg Law, 2022.
[4] State attorney general filings challenging the bankruptcy, March 2022.


This comprehensive review of the litigation landscape surrounding LTL Management LLC underscores the intricate legal tactics, judicial responses, and strategic considerations shaping the case's outcome and its broader implications in corporate bankruptcy law.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.